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Abstract
Study Objectives: Sodium oxybate (SXB) is a GABAergic agent widely used as off-label treatment in pediatric type 1 narcolepsy 
(NT1). Here, we aimed at analyzing by wrist actigraphy the sleep/wake profile of NT1 children and adolescents in drug-naïve 
condition and after 1 year of SXB treatment. As secondary aim, we investigated changes on sleepiness, cataplexy, and children’s 
anthropometric profile after 1 year of SXB treatment.
Methods: Twenty-four drug-naïve NT1 children underwent 7 days of actigraphy during the school week. Information on sleepiness, 
narcolepsy symptoms, and anthropometric features were collected during the same week with questionnaires and semistructured 
clinical interview. Children started SXB treatment and underwent a second evaluation encompassing actigraphy, clinical interview, 
questionnaires, and anthropometric assessment after 1 year of stable treatment.
Results: Actigraphy effectively documented an improvement of nocturnal sleep quality and duration coupled with a reduction of 
diurnal total sleep time, nap frequency, and duration at 1 year follow-up. Reduction of sleepiness, cataplexy frequency and severity, 
and weight loss, mainly in obese and overweight NT1 children, were also observed at the 1 year follow-up.
Conclusions: Actigraphy objectively documented changes in nocturnal sleep quality and diurnal napping behavior after 1 year of 
SXB treatment, thus representing a valid approach to ecologically assess SXB treatment effect on NT1 children’s sleep/wake profile. 
NT1 symptoms severity and children’s anthropometric features also changed as expected. Actigraphy offers the possibility to 
longitudinally follow up children and has potential to become a key tool to tailor treatment in pediatric patients.
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Statement of Significance
Sodium oxybate (SXB) is a drug that currently displays a major role in the off-label treatment of pediatric type 1 narcolepsy (NT1) 
due to its effect on multiple symptoms simultaneously. Nonetheless, periodic follow-ups are required for optimal disease manage-
ment, which so far have been conducted almost exclusively through subjective assessments. We showed, for the first time, that 
actigraphy could be a valid method for in-field assessment of SXB effect, as it depicts changes in NT1 children’s sleep/wake profile 
consistent with those documented by sleep-laboratory tests in adult patients. Additionally, our study confirms that SXB treatment is 
associated with a reduction of sleepiness and cataplexy severity and significant weight loss in obese or overweight children.
SLEEPJ, 2018, 1–7
doi: 10.1093/sleep/zsy050
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Introduction
Pediatric type 1 narcolepsy (NT1) is a chronic neurological dis-
order caused by the loss of the hypothalamic hypocretinergic 
neurons mirrored by low/undetectable levels of the neuropep-
tide hypocretin-1 in the cerebrospinal fluid (CSF Hcrt-1) [1, 2].
The loss of hypocretinergic signaling causes the inability 
to sustain wakefulness for long periods and daily episodes of 
undelayable sleep (excessive daytime sleepiness) [1], as well as 
the inability to maintain an uninterrupted nocturnal sleep (dis-
rupted nocturnal sleep) [3], resulting in the loss of the bounda-
ries between sleep and wake. Manifestations of full-blown or 
dissociated rapid eye movement (REM) sleep during wakeful-
ness (sleep onset REM periods—SOREMPs, cataplexy, sleep par-
alysis, hypnagogic/hypnopompic hallucinations) complete the 
clinical pictures of NT1 [4].
NT1 most often arises during childhood or adolescence [5]. 
Currently, the pharmacological treatment of pediatric NT1 is 
based on off-label drugs [6], some of these registered to treat 
NT1 symptoms in adult patients [7–9]. Sodium oxybate (SXB) is a 
powerful GABAergic compound that affects multiple NT1 symp-
toms simultaneously (i.e. diurnal hypersomnolence, cataplexy, 
and disrupted nighttime sleep) [10] and has been approved 
by the US Food and Drug Administration and the European 
Medicine Agency. Several studies confirmed SXB effects in NT1 
children, showing a safety profile comparable to that reported 
for adults [10–13]. Hence, SXB is increasingly being used as 
an off-label treatment in pediatric NT1, often associated with 
behavioral therapy (i.e. scheduled naps) [14].
SXB treatment in NT1 children and adolescents requires a 
tailored titration and, possibly, periodic objective assessment 
through nocturnal video-polysomnography and maintenance 
of wakefulness test as in adults. However, these expensive and 
time-demanding approaches can be difficult to perform on chil-
dren and may not accurately inform on how children manage 
sleep and sleepiness in everyday life [15, 16].
Recently, several studies have successfully applied actigra-
phy in the clinical work-up of adult and pediatric NT1 [17–19].
Actigraphy is a wearable technology that allows the indirect 
assessment of sleep in the participant’s natural environment 
and has been widely used to assess drug-induced changes in 
sleep/wake and motor activity profile [20]. In the field of NT1, 
actigraphy proved reliable in assessing wake-promoting medi-
cation effects and has been proposed as an alternative to poly-
somnography to assess SXB effects in adult patients [21, 22].
The present study aims were as follows: (1) to explore 
whether at-home actigraphy can represent a valid method to 
objectively assess SXB effects on NT1 children’s sleep/wake 
profile and (2) to assess changes associated with 1 year of SXB 
treatment on sleepiness, cataplexy, NT1-associated symptoms 
(sleep paralyses, hypnagogic/hypnopompic hallucinations, and 
nightmares), and children’s anthropometric profile.
Methods
Participants
The study included 24 participants (13 males) aged <18  years 
(mean age: 12.20  ±  2.95  years, range: 7.10–17.03) with a final 
diagnosis of NT1 based on clinical history, neurophysiological 
(24  hr continuous PSG monitoring and multiple sleep latency 
test—MSLT) and biochemical (Hcrt-1) findings, according to 
the International Classification of Sleep Disorders, 3rd Edition 
(ICSD-3) criteria [1].
All children were drug-naïve at the time of evaluation and 
underwent our standardized diagnostic protocol, encompassing 
at least 7 days of at-home actigraphy before diagnostic hospital-
ization [17, 23]. Baseline actigraphic data from 12 NT1 patients 
from the present cohort were previously published in a study 
investigating the features of the circadian motor activity profile 
in pediatric NT1 [19].
All children had video-documented cataplexy [24], carried 
the human leukocyte antigen (HLA) DQB1*06:02, and displayed 
low (≤110 pg/mL) or undetectable CSF Hcrt-1 levels (lumbar 
puncture not performed in two children with in-laboratory 
documented cataplexy). Children and their relatives provided 
written informed consent. The study was approved by the Local 
Health Trust’s Ethics Committee (Comitato Etico Interaziendale 
Bologna-Imola, CE-BI, Prot. Num. 17009).
Procedures
Children and a family member attended an educational ses-
sion on SXB conducted by a sleep specialist (G.P. or F.P.), and on 
this occasion children completed questionnaires and under-
went a semistructured clinical interview on cataplexy and 
NT1-associated symptoms. Anthropometric features (height, 
weight, and BMI) were collected by using a portable stadiom-
eter (Harpenden Portable Stadiometer). Height, weight, and BMI 
z-score (BMI adjusted for sex and age) were calculated for all 
patients [25]. Underweight was defined as BMI < 5th percentile, 
normal weight as BMI > 5th and < 85th percentile, overweight 
between 85th and 95th percentile, and obesity as BMI > 95th per-
centile [26].
Patients started treatment with a dose of 1  +  1  g taken at 
bedtime and 3.5 hr away. SXB titration was made on the basis 
of weekly telephonic contacts between the children’s relatives 
and the prescribing physician, and personalized until reaching 
an “optimal” dose (i.e. the dose that displayed the best balance 
between efficacy and tolerability). Detailed SXB dosing regimen 
for each patient is reported in Supplementary Table S1. Children 
were routinely followed up every 3 months through outpatient 
clinical evaluation and after 1 year of SXB treatment underwent 
a second evaluation comprising at-home actigraphy, question-
naires, semistructured clinical interview, and anthropometric 
assessment.
Actigraphy
Patients wore the Micro Motionlogger Watch actigraph 
(Ambulatory Monitoring, Inc., Ardsley, NY), consisting in a tri-
axial accelerometer with case temperature and environment 
light sensors, at the nondominant wrist. Devices were initial-
ized in zero-crossing mode to quantify motor activity exceeding 
0.01 g at a sampling frequency of 32 Hz, changes in acceleration 
were integrated and expressed in 1 min epochs, and sleep and 
wake epochs were estimated by using the validated algorithms 
developed by Sadeh [27].
Children were monitored during the school week and dur-
ing the same season at both baseline and follow-up evaluations 
to minimize environmental influences; children were asked to 
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wear the device continuously across 24  hr, except when tak-
ing bath/shower, and to maintain their habitual sleep/wake 
schedule during the recording. In parallel, they had to fill in a 
daily sleep diary and mark time in and out of bed and diurnal 
naps by pressing the event-marker button on the device. At the 
1 year follow-up evaluation, we also asked children to mark the 
moment when they took the first and the second dose of SXB by 
pressing the event-marker button.
Parents were asked to assist children in completing the 
sleep diary and with the event-marker procedure, if necessary. 
Combining event-marked points and sleep diary information 
(if children omitted to push the event-marker), an experienced 
scorer identified the major nocturnal sleep period and the diur-
nal sleep episodes. Actigraphic recordings were split into night-
time and daytime periods based on individual bedtime and 
wake time, and mean actigraphic parameters were computed 
over 7 days in all participants for baseline and 1 year follow-up 
evaluations.
As previously reported [19], we considered the following acti-
graphic parameters: bedtime, wake time, midpoint, time in bed 
(TIB), estimated total sleep time (eTST), estimated wake after 
sleep onset (eWASO), estimated sleep efficiency, estimated noc-
turnal awakenings frequency, estimated prolonged (lasting more 
than 5 min) nocturnal awakenings frequency, estimated longest 
sleep (longest continuous episode scored as sleep), sleep motor 
activity (SMA), daytime motor activity (DMA), estimated daytime 
total sleep time (eDTST), estimated nap frequency (with a nap 
defined as an interval of at least 10 min up to 3 hr scored as sleep, 
preceded and followed by a period of at least 30 min scored as 
wake), estimated mean nap duration, and 24 hr estimated total 
sleep time (e24hTST—sum, in minutes, of all epochs scored as 
sleep in both nighttime and daytime periods). Finally, we carried 
out a nap analysis by dividing the daytime period into three seg-
ments (8:00–13:00, 13:00–18:00, and 18:00–22:00) and computing 
nap frequency and mean nap duration for each segment.
Questionnaires and semistructured interview
At baseline and at 1 year follow-up evaluations, children under-
went a semistructured interview and completed the Epworth 
Sleepiness scale for children and adolescents (ESS-CHAD) [28], 
and the Italian version of the reduced Morningness–Eveningness 
questionnaire for children and adolescents (rMEQ-CA) [29].
The semistructured interview lasted 30–45  min and inves-
tigated cataplexy features, presence of NT1-associated symp-
toms, and occurrence of nocturnal enuresis and sleepwalking. 
Parents were present and authorized to assist the children in 
providing answers if needed.
The following cataplexy features were explored: frequency of 
cataplectic attack, expressed on a 5-point Likert scale (1: ≥1/day; 
2: ≥1/week; 3: ≥1/month; 4: ≥1/in 3 months; 5: ≥1/in 6 months); 
cataplectic attack duration (1: ≤10 s; 2: from 30 to 60 s; 3: from 60 
to 120 s), body-involvement during cataplectic attacks (partial: 
momentary weakness without postural dyscontrol; generalized: 
momentary weakness with fall to the ground), and questions 
(dichotomous) on the presence of falls to the ground and of 
“cataplectic status/facies” (long-lasting, continuous/subcontin-
uous, cataplectic attack with prominent facial involvement) [30].
Presence or absence of the following NT1 associated symp-
toms was explored: sleep paralysis, hypnagogic/hypnopompic 
hallucinations, automatic behaviors, and nightmares [31].
Statistical analysis
Data were explored with descriptive statistics (mean ± SD and 
frequency). To assess whether statistically significant changes 
occurred from baseline to 1  year follow-up in questionnaire 
scores, anthropometric features, and actigraphic parameters, 
the Student’s t-test for paired-samples was performed; in case 
of statistically significant results, the effect size (Cohen’s d) was 
computed. Differences from baseline to 1 year follow-up evalu-
ation in chronotype and BMI category distribution were explored 
by means of the McNemar test. Regarding the semistructured 
interview data, we carried out the Wilcoxon signed-rank test 
for variables expressed on ordinal scale and the McNemar test 
for categorical variables. p-Values below 0.05 were considered 
statistically significant. All statistical analyses were conducted 
using IBM SPSS Statistics 19 software (SPSS, Inc., Chicago, IL).
Results
Actigraphic data at baseline and 1 year follow-up
Actigraphic parameters at baseline and 1  year follow-up are 
reported in Table 1. At 1 year follow-up, children woke up earlier 
and displayed a significant reduction of TIB, whereas no differ-
ences emerged in bedtime and midpoint of sleep. All nighttime 
actigraphic parameters showed significant changes from base-
line to 1 year follow-up, with NT1 children displaying increased 
eTST and estimated sleep efficiency, reduced time spent in 
eWASO and SMA levels, decreased frequency of both brief and 
prolonged awakenings, and increased duration of the longest 
estimated nocturnal sleep. Regarding daytime period, at 1 year 
follow-up, NT1 children spent less time sleeping (eDTST) and 
took fewer and shorter naps, whereas DMA levels did not sig-
nificantly change from baseline.
Despite a slight increase at 1 year follow-up, no significant 
differences emerged in the total amount of time spent sleeping 
across 24 hr (e24hTST). Finally, children napping behavior dis-
played significant changes at 1 year follow-up, with a reduction 
in mean afternoon (13:00–18:00) nap duration and in evening 
(18:00–20:00) nap frequency; no further significant differences 
emerged.
Clinical and anthropometric data at baseline and 
1 year follow-up
At baseline, 66 per cent of children were overweight or obese 
(33% obese and 33% overweight, respectively).
Demographics, clinical, anthropometric data and question-
naire scores at baseline, and 1  year follow-up are reported in 
Table 2. Significant changes from baseline to 1 year follow-up 
were observed in ESS-CHAD score but not in rMEQ-CA score, nor 
in chronotype distribution. Significant changes were observed in 
BMI, BMI and weight z-scores, and in the BMI category distribu-
tion with five (21%) overweight children at baseline, presenting 
with a BMI within the normal range at 1 year follow-up, three 
(13%) obese children at baseline presenting with a BMI within 
the overweight range at 1  year follow-up, and one (4%) obese 
patient at baseline presenting with a BMI within the normal 
range at 1 year follow-up.
Data of the semistructured interview are reported in Table 3. 
SXB treatment was associated with a significant reduction of 
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cataplexy frequency and changes in its features, with predom-
inantly partial body-involvement during attacks, decreased 
occurrence of falls to the ground and of spontaneous cata-
plectic status/facies, whereas typical cataplexy duration was 
unchanged. SXB treatment was associated with decreased 
occurrence of automatic behaviors and nightmares, whereas 
no significant effect was observed on sleep paralysis, hallucina-
tions, and sleepwalking. Finally, SXB treatment was associated 
with increased occurrence of nocturnal enuresis.
Discussion
This study is the first that evaluated SXB effect in pediatric NT1 
patients by means of in-field actigraphy.
Our actigraphic findings are comparable with previous PSG 
studies on adult NT1 in showing that SXB treatment is associ-
ated with a significant improvement in nocturnal sleep continu-
ity (decreased eWASO and awakenings frequency, increased sleep 
efficiency, and estimated longest nocturnal sleep duration) and 
duration (increased eTST) [9, 32]. The lack of neurophysiological 
studies investigating SXB-induced changes on NT1 children diur-
nal profile precludes the possibility to directly compare our in-
field findings with literature data. Our results documented that 
SXB treatment is associated with a reduction in time spent asleep 
during daytime without any effect on DMA levels. Nap analysis 
further characterized SXB-induced changes on NT1 children day-
time behavior, disclosing a decrease in mean afternoon nap dur-
ation and in evening nap frequency, with the latter most likely 
reflecting the enhancement of homeostatic process.
NT1 children were assessed during school week and analo-
gous season at both baseline and 1 year follow-up evaluations; 
this strengthens our results inasmuch minimize possible varia-
tions in sleep duration, timing of circadian phase, and daytime 
behavior related to seasonal changes.
Changes in NT1 children’s actigraphic sleep/wake profile 
associated with SXB treatment were paralleled by changes in 
sleepiness, cataplexy, and anthropometric features. Indeed, SXB 
treatment was associated with a reduction of subjective sleepi-
ness level, automatic behaviors, and of cataplexy frequency and 
severity.
We also confirmed the overrepresentation of obesity (33.3%) 
and overweight (33.3%) among drug-naïve NT1 children [33–35], 
compared with the general Italian population (obesity 9.8% and 
overweight 20.9%, respectively) [36]. Moreover, our results con-
firm that 1 year of SXB treatment is associated with a significant 
weight loss in obese and overweight children, without affecting 
the anthropometric profile of normal-weight NT1 children [35].
Since DMA levels did not significantly change from baseline 
to 1 year follow-up, weight reduction can likely be ascribed to 
different SXB-induced changes such as the stimulation of lipoly-
sis or the restoration of slow-wave sleep, rather than to changes 
in daytime behavior [32, 37].
Treatment with SXB was not associated with decreased 
occurrence of sleep paralysis and hypnagogic/hypnopompic 
hallucinations, but with a reduced occurrence of nightmares: in 
this regard, previous studies highlighted an increased frequency 
of nightmares in NT1 that can prove very burdensome in adult 
patients and reasonably even more in children [31].






Mean ± SD P ES
Sleep timing
Bedtime 23:13 ± 01:09 23:16 ± 00:32 ns
Wake time 08:01 ± 01:19 07:06 ± 00:38 <0.001 0.76
Midpoint 03:37 ± 01:09 03:10 ± 00:29 ns
TIB, min 526.61 ± 55.24 470.77 ± 39.95 <0.0001 1.10
Nighttime period
eTST, min 330.80 ± 53.77 373.97 ± 51 <0.001 −0.81
eSleep efficiency 62.91 ± 8.89 79.65 ± 8.90 <0.0001 −1.61
eWASO, min 179.69 ± 48.83 81.61 ± 41.19 <0.0001 1.78
eAwakenings, n 32.88 ± 8.15 16.83 ± 4.08 <0.0001 2.44
eProlonged awakenings, n 10.08 ± 2.57 5.17 ± 1.97 <0.0001 1.98
SMA, counts 33.69 ± 12.47 18.69 ± 7.34 <0.0001 1.15
eLongest sleep, min 64.27 ± 12.51 128.43 ± 31.46 <0.0001 −2.67
Daytime period
DMA, counts 202.15 ± 22.47  198.63 ± 19.32 ns
eDTST, min 67.90 ± 26.95 42.79 ± 18.24 <0.0001 1.01
eNap, n 8.13 ± 3.42 6.46 ± 2.64 <0.05 0.43
eNapD, min 51.85 ± 13.05 36.94 ± 12.89 <0.001 0.79
e24hTST, min 398.71 ± 59.95 416.76 ± 48.57 ns
Nap analysis
Morning eNap, n 2.38 ± 1.93 1.56 ± 2.22 ns
Morning eNapD, min 24.99 ± 10.32 31.10 ± 9.57 ns
Afternoon eNap, n 5 ± 1.60 4.23 ± 1.77 ns
Afternoon eNapD, min 58.45 ± 18.52 36.82 ± 14.55 <0.0001 1.08
Evening eNap, n 2.56 ± 1.75 1.25 ± 1.39 <0.05 0.45
Evening eNapD, min 48.30 ± 12.26 44.88 ± 18.26 ns
NT1 = type 1 narcolepsy; SXB = sodium oxybate; ES = Cohen’s d; TIB = time in bed; eTST = estimated total sleep time; eWASO = estimated wake after sleep onset; 
SMA = mean activity counts during TIB; DMA = mean activity counts during daytime; eDTST = estimated daytime total sleep time; eNapD = mean nap duration; 
e24hTST = sum of all epoch scored as sleep in both nighttime and daytime periods.
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In our sample, SXB treatment did not turn out to be associ-
ated with increased occurrence of sleepwalking, but we confirm 
an association with nocturnal enuresis (up to 25% of children 
with at least one episode) [10, 12].
In our study, treatment compliance was excellent: SXB was 
overall well tolerated by NT1 children and, apart from nocturnal 
enuresis, the most commonly reported side effect was irritabil-
ity which, however, was not deemed burdensome enough (by 
the physician and/or children/parents) to withdraw treatment.
Although SXB proved effective in all evaluated NT1 children, 
with an outstanding reduction of sleepiness and cataplexy and a 
major impact on children’s sleep/wake profile, a significant por-
tion of our sample (50%) still presented with an ESS-CHAD score 
of >10 (a validated cutoff) at 1 year follow-up [38], and all children 
had daily long-lasting naps in the early afternoon, though with 
shorter duration compared with baseline. These results highlight 
two common issues in pediatric NT1 management: first, in up to 
50 per cent of NT1 children SXB monotherapy is not sufficient 
to flatten hypersomnolence to nonpathological levels. In these 
cases, the co-administration of wake-promoting drugs has been 
shown to be overall well tolerated and more efficacious than each 
drug alone [39]. Second, although during both the SXB educational 





P ESMean ± SD Mean ± SD
Male/female 13/11
Age at NT1 onset, years 9.09 ± 3.03
Age at observation, years 12.20 ± 2.95 13.19 ± 2.98
Diagnostic delay, years 3.10 ± 3.21 range 0.02–11.10
MSLT-sl, min 3.35 ± 2.89 n/a
SOREMP, n 4.54 ± 0.78 n/a
CSF Hcrt-1, pg/mL (n = 22) 14.7 ± 17.21 range 0–44.6 n/a
HLA DQB1*0602 positivity 24/24
Height, cm 1.56 ± 0.16 1.61 ± 0.15
Weight, kg 65.58 ± 24.70 60.90 ± 20.78
BMI 26.17 ± 7.14 23.08 ± 5.43 <0.0001 1.00
Height z-score 0.55 ± 1.09 0.66 ± 1.03 ns
Weight z-score 1.46 ± 1.23 0.82 ± 1.33 <0.0001 1.05
BMI z-score 1.38 ± 1.12 0.59 ± 1.33 <0.0001 1.24
BMI category (underweight|normal|over|obese) 0|8|8|8 0|14|6|4 0.029†
Questionnaire
ESS-CHAD 15.71 ± 2.56 10.29 ± 3.52 <0.0001 1.33
rMEQ-CA 15.17 ± 3.97 16 ± 3.08 ns
Chronotype (m|i|e) 7|13|4 7|16|1 ns†
NT1 = type 1 narcolepsy; SXB = sodium oxybate; ES = Cohen’s d; MSLT-sl = mean sleep latency at MSLT; SOREMPs = sleep-onset REM periods at MSLT; CSF Hcrt-1 = cere-
brospinal fluid hypocretin-1; BMI = body mass index; ESS-CHAD = Epworth sleepiness scale for children and adolescent; rMEQ-CA = reduced Morningness–Eveningness 
questionnaire for children and adolescent; Chronotype (m = morning type; i = intermediate type; e = evening type). †McNemar’s test.




NT1 children (n = 24) P
Cataplexy frequency, (%) ≥ 1/day 83.3 8.3 <0.0001†
≥ 1/week 12.5 41.7
≥ 1/month 4.2 25.0
≥ 1/in 3 months 0 8.3
≥ 1/in 6 months 0 16.7
Cataplexy duration, (%) < 10 s 79.2 95.8 ns†
30 to 60 s 16.7 4.2
60 to 120 s 4.2 0
Cataplectic facies/status, affected (%) 62.5 16.7 <0.001‡
Partial/Generalized cataplexy, presence (%) 20.8/79.2 95.8/4.2 <0.0001‡
Falls to the ground, presence (%) 70.80 4.2 <0.0001‡
Automatic behaviors, affected (%) 79.2 29.2 <0.0001‡
Sleep Paralyses, affected (%) 33.3 12.5 ns‡
Hallucinations, affected (%) 41.7 20.8 ns‡
Sleepwalking, affected (%) 8.3 12.5 ns‡
Nocturnal enuresis, affected (%) 0 25 <0.05‡
Nightmare, affected (%) 45.8 20.8 <0.05‡
NT1 = type 1 narcolepsy; SXB = sodium oxybate.
†Wilcoxon signed-rank test; ‡McNemar’s test.
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session and routine follow-up evaluations children and their par-
ents received general instruction on the diurnal sleep schedule 
[40], actigraphy documented that the spontaneous establishment 
of a napping strategy has been rather scarce, with children con-
tinuing to display long-lasting sleep episodes in the afternoon, 
immediately after lunch. Illustrative actigram of a patient at base-
line and 1 year follow-up is reported in Supplementary Figure S1. 
Although behavioral therapy is required for optimal symptom 
control, our data suggest that NT1 children need to be trained to 
a regular napping schedule in the framework of a comprehen-
sive educational program. This issue, together with the possible 
impact of physical activity programs, should be explored by fur-
ther longitudinal studies in patients with and without treatment.
Some limitations of the present work should be acknowl-
edged. First, SXB effect was assessed by integrating different 
sources of information (i.e. self-assessment questionnaire 
and semistructured interviews). Recently, a narcolepsy sever-
ity scale has been developed to quantify the main narcolepsy 
symptoms (cataplexy, hypnagogic/hypnopompic hallucina-
tions, sleep paralysis, and disrupted nighttime sleep) and their 
changes with treatment in adult NT1 [41]. The authors planned 
to validate this scale also for NT1 children and adolescent, but 
unfortunately it was not yet available at the time of our study.
Second, at 1 year follow-up, neurophysiological evaluations 
were not performed, precluding the possibility of exploring 
whether changes in the 24  hr activity profile correlated with 
documented changes in nocturnal sleep dynamics and diurnal 
sleep propensity.
In conclusion, in this study we show that in-field actigraphy 
is a valid method to ecologically assess SXB-associated changes 
on NT1 children’s sleep/wake profile. Actigraphy has the poten-
tial to become a key tool to tailor treatment in children suffering 
from this chronic disease; furthermore, the modification of chil-
dren’s sleep/wake profile might be considered a potential out-
come measure in controlled pharmacological studies. Further 
studies are required to explore whether actigraphy can be suffi-
ciently sensitive for assessing effects of pharmacological poly-
therapy in pediatric NT1.
Supplementary Material
Supplementary material is available at SLEEP online.
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